Enanta Pharmaceuticals
ENTA
193 hedge funds and large institutions have $1.75B invested in Enanta Pharmaceuticals in 2018 Q2 according to their latest regulatory filings, with 30 funds opening new positions, 75 increasing their positions, 57 reducing their positions, and 17 closing their positions.
76% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 17
47% more capital invested
Capital invested by funds: $1.19B → $1.75B (+$556M)
32% more repeat investments, than reductions
Existing positions increased: 75 | Existing positions reduced: 57
29% more call options, than puts
Call options by funds: $11.5M | Put options by funds: $8.92M
7% more funds holding
Funds holding: 181 → 193 (+12)
1.34% more ownership
Funds ownership: 76.95% → 78.29% (+1.3%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$53.6M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$23M |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$16M |
| 4 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$16M |
| 5 |
Prudential Financial
Newark,
New Jersey
|
+$8.52M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
|
-$36.7M |
| 2 |
First Manhattan
New York
|
-$30.2M |
| 3 |
KAM
Krensavage Asset Management
New York
|
-$22M |
| 4 |
Man Group
London,
United Kingdom
|
-$14.7M |
| 5 |
Millennium Management
New York
|
-$8.59M |
ENTA Hedge Fund Activity: Q2 2018 in Review
193 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in Enanta Pharmaceuticals (ENTA) for Q2 2018, worth a combined $1.75B — up 47% from $1.19B a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new ENTA positions and 17 closed out — a net gain of 13 holders — while 75 added to existing stakes and 57 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $53.6M. The largest seller was Janus Henderson Group, cutting an estimated $36.7M.
- 193 institutional investors held Enanta Pharmaceuticals (ENTA) as of Q2 2018, up from 181 in Q1 2018.
- Funds reported $1.75B of Enanta Pharmaceuticals stock for Q2 2018, up 47% quarter-over-quarter.
- 30 funds opened new Enanta Pharmaceuticals positions in Q2 2018 and 17 closed out, a net change of +13 holders.
- The largest Enanta Pharmaceuticals buyer in Q2 2018 was T. Rowe Price Associates, an estimated $53.6M added.
- The largest Enanta Pharmaceuticals seller in Q2 2018 was Janus Henderson Group, an estimated $36.7M sold.
Based on aggregated 13F filings for Q2 2018.